Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynaecology,Oncology
Reference36 articles.
1. Cancer Facts and Figures 2017. Atlanta: American Cancer Society; 2017.
2. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer;Gillen;Gynecol. Oncol.,2017
3. Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE working group;Vercelli;Crit Rev Oncol Hematol.,2000
4. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study;Pignata;Crit Rev Oncol Hematol.,2009
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial;International Journal of Radiation Oncology*Biology*Physics;2024-01
2. Real-world data in patients with BRCA mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors;ecancermedicalscience;2023-11-21
3. Safety of PARP inhibitors as maintenance therapy in ovarian cancer;Expert Opinion on Drug Safety;2023-09-14
4. Olaparib and advanced ovarian cancer: Summary of the past and looking into the future;Frontiers in Pharmacology;2023-04-21
5. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial;European Journal of Cancer;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3